Viracta Therapeutics, Inc. financial data

Symbol
VIRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2533 S Coast Hwy 101, Suite 210, Cardiff, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
SUNESIS PHARMACEUTICALS INC (to 3/2/2021)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 118 % -72.6%
Debt-to-equity 494 %
Return On Equity -680 % -554%
Return On Assets -114 % -95.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.7M shares +2.9%
Common Stock, Shares, Outstanding 39.7M shares +2.9%
Entity Public Float 50.2M USD -65.5%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.6M shares +2.3%
Weighted Average Number of Shares Outstanding, Diluted 39.6M shares +2.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 14.1M USD -21.7%
Operating Income (Loss) -47.2M USD +3.07%
Net Income (Loss) Attributable to Parent -43.3M USD +9.09%
Earnings Per Share, Basic -1.1 USD/shares +11.3%
Earnings Per Share, Diluted -1.1 USD/shares +38.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.1M USD +2.11%
Cash, Cash Equivalents, and Short-term Investments 21.1M USD -66.5%
Assets, Current 21.8M USD -66.2%
Property, Plant and Equipment, Net 111K USD -49.1%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 44K USD -96.9%
Assets 22M USD -66.9%
Accounts Payable, Current 1.82M USD -23.1%
Employee-related Liabilities, Current 739K USD -68.3%
Accrued Liabilities, Current 9.85M USD +15.8%
Liabilities, Current 28.6M USD -21.6%
Operating Lease, Liability, Noncurrent 73K USD +2.82%
Liabilities 28.6M USD -21.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9K USD
Retained Earnings (Accumulated Deficit) -295M USD -17.2%
Stockholders' Equity Attributable to Parent -6.62M USD -122%
Liabilities and Equity 22M USD -66.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85M USD +30.8%
Net Cash Provided by (Used in) Financing Activities -6.6M USD -141%
Net Cash Provided by (Used in) Investing Activities 14.2M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 39.7M shares +2.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.1M USD +2.11%
Interest Paid, Excluding Capitalized Interest, Operating Activities 851K USD +47%
Deferred Tax Assets, Valuation Allowance 73.2M USD +20.6%
Deferred Tax Assets, Gross 73.3M USD +20.5%
Operating Lease, Liability 73K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -43.2M USD +8.99%
Lessee, Operating Lease, Liability, to be Paid 73K USD -85.7%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 294K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 110K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +87.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Preferred Stock, Shares Issued 0 shares -100%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.78M USD +17.3%
Operating Lease, Payments 209K USD -66.7%
Additional Paid in Capital 289M USD +4.35%
Preferred Stock, Shares Outstanding 0 shares -100%
Depreciation, Depletion and Amortization 110K USD -9.84%
Share-based Payment Arrangement, Expense 6.25M USD -22.3%
Interest Expense 3.18M USD +8.26%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%